Accumulating lines of evidence demonstrated that predictive biomarkers play an important role in predicting response and safety of anti-PD-1/PD-L1 therapy and in the identification of lung cancer patients who will benefit from anti-PD-1/PD-L1 immunotherapy. Here, CD274 is linked to lung carcinoma.